Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Target guided synthesis using DNA nano-templates for selectively assembling a G-quadruplex binding c-MYC inhibitor


The development of small molecules is essential to modulate the cellular functions of biological targets in living system. Target Guided Synthesis (TGS) approaches have been used for the identification of potent small molecules for biological targets. We herein demonstrate an innovative example of TGS using DNA nano-templates that promote Huisgen cycloaddition from an array of azide and alkyne fragments. A G-quadruplex and a control duplex DNA nano-template have been prepared by assembling the DNA structures on gold-coated magnetic nanoparticles. The DNA nano-templates facilitate the regioselective formation of 1,4-substituted triazole products, which are easily isolated by magnetic decantation. The G-quadruplex nano-template can be easily recovered and reused for five reaction cycles. The major triazole product, generated by the G-quadruplex inhibits c-MYC expression by directly targeting the c-MYC promoter G-quadruplex. This work highlights that the nano-TGS approach may serve as a valuable strategy to generate target-selective ligands for drug discovery.


Small molecules are fundamental probes for studying biological system. Considering the dynamic nature of the biological macromolecules, the development of small molecules that can interact with biological targets with high affinity and selectivity has always been challenging and time consuming. Target Guided Synthesis (TGS) is a powerful approach to discover novel and selective small molecule binders for biological targets by combining the synthesis and screening into a single step1. It uses a biological target to synthesize its own best binders from a series of small molecule fragments, functionalized with complementary reacting groups. In a pioneering work, Sharpless and co-workers developed in situ click chemistry, a kinetically controlled TGS approach in which the enzyme acetylcholinesterase was used as the target to assemble its potent small molecule inhibitors from a pool of azide and alkyne building blocks2,3. In TGS, the azide and alkyne fragments undergo Huisgen 1,3-dipolar cycloaddition (Click reaction) in the presence of a catalytic target that brings the azide and alkyne building blocks into close proximity with correct spatial orientation to generate one of the triazole regioisomers in the absence of any metal catalyst. Therefore, small molecules identified by TGS are expected to show high binding affinity as well as specificity for the target as they are synthesized by a specific reaction in which the active site of the biological target controls the assembly of the best binding fragments. The majority of TGS approaches, reported to date, use various enzymes as the target to assemble their potent inhibitors4,5,6,7. Only two examples are reported so far using nucleic acids as the targets8,9. However, these solution phase TGS methods have some limitations like poor isolation of the lead compounds from the reaction mixture comprising the target and fragment library and lack of reusability of the target for multiple rounds of templated synthesis.

We anticipated that the use of magnetic nanoparticle supported DNA sequences as the targets could overcome such shortcomings; the in situ lead compounds could be easily isolated by simple magnetic decantation and the DNA templates could be easily recovered and recycled. In addition, the DNA sequences immobilized on the nanoparticle surface would greatly enhance the rate of reaction between small molecule fragments by providing a larger surface area with more numbers of localized DNA templates.

In the present study, we describe an azide-alkyne cycloaddition based TGS approach using c-MYC G-quadruplex and control duplex DNA monolayers assembled on gold-coated magnetic-nanoparticles as the templates. The c-MYC G-quadruplex present in the NHE III1 region upstream of the P1 promoter is believed to be involved in the complex regulation of c-MYC expression and thus considered as an attractive target for anticancer therapeutics10,11,12,13,14,15. Small molecules capable of binding c-MYC G-quadruplex have been developed using multistep organic syntheses16,17,18,19. Although many ligands are known to stabilize G-quadruplexes and modulate gene expression, only recently a benzofuran derivative is reported to inhibit c-MYC expression by G-quadruplex dependent mechanism20. Our findings demonstrate that the G-quadruplex nano-template can be efficiently used in TGS for the rapid identification of a selective triazole ligand for the c-MYC G-quadruplex. Using biophysical and cellular assays, we also establish that this compound can inhibit the c-MYC expression via G-quadruplex binding.


Preparation of DNA functionalized Au@Fe3O4 nanoparticles

To develop TGS using DNA nano-templates, the thiolated DNA sequences were immobilized on the surface of gold-coated magnetic nanoparticles (Au@Fe3O4). Iron oxide based magnetic nanoparticles (Fe3O4 MNPs) have shown good promise in biological applications as they are non-toxic, naturally available and easily synthesizable with superior magnetic and chemical properties21,22,23,24,25,26. Gold coating on these nanoparticles improves the stability of the nanoparticles in solution, makes them biocompatible and provides an outer layer for covalently tethering thiolated biomolecules on nanoparticle surfaces by chemisorption. The Au@Fe3O4 nanoparticles were prepared by citrate reduction of gold salt on Fe3O4 nanoparticles (see Methods)27.

The thiolated G-quadruplex and duplex DNA sequences were self-assembled as a monolayer by covalent bonding with the surface of the gold shell (Fig. 1a)28, which is confirmed by the ultraviolet-visible absorption spectra (Fig. 1b). The Fe3O4 MNP spectrum showed no characteristic peak in the visible region, while the dispersion of Au@Fe3O4 NPs in 100 mM Tris-KCl buffer (pH 7.4) displayed a SPR absorption band 535 nm (refs 29, 30, 31). The DNA linked Au@Fe3O4 NPs (G4·Au@Fe3O4 and dsDNA·Au@Fe3O4) also showed characteristic SPR bands of Au at 535 nm. The G4·Au@Fe3O4 and dsDNA·Au@Fe3O4 displayed absorption peaks near 270 and 280 nm, respectively, suggesting DNA modification on the MNP surface (Fig. 1b). The surface functionalization of the nanoparticles with thiolated c-MYC G4 DNA was further confirmed by CD spectroscopy. The CD spectrum of G4·Au@Fe3O4 nano-template exhibited a positive peak at 260 nm and a negative peak at 240 nm, which indicates that it retains the parallel conformation of the c-MYC quadruplex (Fig. 1c). The DNA-linked nanoparticles exhibited paramagnetic properties of Fe3O4 MNPs (Supplementary Fig. 1). Then we characterized the DNA-linked nanoparticles by transmission electron microscopy (TEM) and atomic force microscopy (AFM) experiments. Both the Fe3O4 and Au@Fe3O4 were nearly spherical and relatively mono-disperse with a mean diameter of 11 and 15 nm, respectively, (Supplementary Fig. 1). The EDX spectra of Au@Fe3O4 NP indicated the presence of both Fe and Au in the particles (Supplementary Fig. 1). The G4·Au@Fe3O4 MNPs also preserved the near spherical shape of the NPs (Fig. 1d). The attachment of thiol-DNA onto Au@Fe3O4 MNPs was further assessed by β-mercaptoethanol (β-ME) mediated thiol exchange reaction that displaced the surface bound c-MYC G4 DNA, visualized by Native PAGE analysis (Supplementary Fig. 2)32.

Figure 1: Characterization of G4·Au@Fe3O4 NPs.

(a) Schematic diagram of formation of c-MYC G-quadruplex (5-SH-G4AG3TG4AG3TG4-3′) and duplex DNA (5-SH-CA5T5GCA5T5G-3′) functionalized Au@Fe3O4 nanoparticles. (b) Absorption spectra of magnetic nanoparticles in Tris-KCl buffer (pH 7.4); blue-Fe3O4 NP, orange-Au@Fe3O4 NP, violet-G4·Au@Fe3O4 and black- dsDNA·Au@Fe3O4 NP. (c) CD spectrum of the thiol-capped c-MYC G-quadruplex oligonucleotide bound nanoparticles (G4·Au@Fe3O4); magenta-10 μM c-MYC G-quadruplex DNA, orange-G4·Au@Fe3O4. (d) TEM image of G4·Au@Fe3O4.

Design and synthesis of azide and alkyne building blocks

To generate high-affinity G-quadruplex ligands, a library of azide and alkyne building blocks was prepared (Fig. 2). The alkynes 1a, 1b and 1c were derived from carbazole, a rigid heteroaromatic ring system present in numerous natural products and pharmacologically active compounds33,34,35,36. The alkyne 1a was prepared in good overall yield from the commercially available carbazole using mono-iodination, N-arylation followed by amide coupling and Sonogoshira reaction (Supplementary Fig. 3). Alkyne 1b was simply prepared from the mono-iodo carbazole by Sonogashira coupling (Supplementary Fig. 4) and alkyne 1c was derived from mono-iodo carbazole by N-alkylation followed by Sonogoshira coupling (Supplementary Fig. 5). The reason for selecting carbazole ring system is that it can interact with the G-quadruplex DNA through ππ stacking interactions with the external G-quartets. Our azide library contains a range of aliphatic and aromatic azides that includes amines (2, 3 and 7), alcohols (4 and 7), simple phenyl ring (5), aromatic aldehyde (8), ester (9) and carboxamide with amine side chains (11). It also contains amino acid and nucleoside derivatives such as prolinamide (10) and guanosine (12). These azide building blocks (212) may interact with G-quadruplex using ππ stacking interactions by the aromatic ring systems and electrostatic interactions by the protonable side chains. The synthesized azide and alkyne library would generate 66 theoretically possible triazole products including 1,4 and 1,5 regioisomers that may interact with the target G-quadruplex.

Figure 2: Design of building blocks for templated cycloaddition.

(a) G4·Au@Fe3O4 NP templated azide-alkyne cycloaddition. (b,c) Structures of carbazole alkynes 1ac and azides 212.

G4·Au@Fe3O4 MNPs templated synthesis

We then evaluated the ability of G4·Au@Fe3O4 to template the metal free 1,3-dipolar cycloaddition. In a typical experiment, a 4:1 mixture of azide and alkyne building blocks 112 were stirred with c-MYC G4·Au@Fe3O4 NPs in Tris-KCl buffer (100 mM, pH 7.4). After 6 days, the reaction mixture was treated with the denaturing agent lithium chloride (LiCl) and heated to 65 °C to unfold the DNA-quadruplex (Supplementary Fig. 6). The HPLC chromatogram of the supernatant collected after magnetic separation of DNA·NPs showed an inseparable complex mixture of compounds with overlapping peaks (Supplementary Fig. 6). Subsequently, the purification protocol was modified by simple heating the mixture at 65 °C without adding LiCl (ref. 37). However, the in situ lead compounds could not be identified as overlapping peaks were obtained in HPLC (Supplementary Fig. 6).

We then modified the separation technique to easily identify and isolate the in situ leads. As the resultant triazole products are expected to bind the G-quadruplex magnetic nano-template, the separation technique was improved to (i) detect each generated triazole leads, enabling the analysis of the complex reaction mixture in an optimum time and (ii) recycle the DNA template for successive azide-alkyne cycloadditions. After incubating the mixture of azide and alkyne fragments 112 with the G4·Au@Fe3O4 MNPs for 6 days, the MNPs along with the newly formed bound products were separated from the reaction mixture using an external magnet and washed three times with 100 mM Tris-KCl buffer to remove the unreacted building blocks. The unreacted fragments remained in the supernatant. The MNPs were then resuspended in 100 mM Tris-KCl buffer, heated to 65 °C to release the products bound with the G-quadruplex nano-template. The DNA-MNPs were separated instantly by magnetic decantation and the supernatant was collected and characterized by HPLC and ESI-MS analysis (Fig. 3, Supplementary Methods).

Figure 3: Selective cycloaddition by G4·Au@Fe3O4 nano-template.

Schematic representation of templated cycloaddition between selective azide and alkyne partners using G4·Au@Fe3O4 nanoparticles.

We observed the formation of three triazole compounds (Tz 1–3 in 62:7:31 percentage ratio) in the presence of the c-MYC G4·Au@Fe3O4 NPs (Fig. 4a). For a comparison, we have performed the TGS reaction with conventional c-MYC G-quadruplex DNA sequence (5-G4AG3TG4AG3TG4-3′), that yielded essentially similar lead compounds which were identified in ESI-MS analysis but overlapping peaks were obtained in HPLC chromatogram. This result validates the use of G4·Au@Fe3O4 MNPs as an alternative template to the homogeneous G-quadruplex DNA for the templated synthesis of G-quadruplex ligands. This method thus provides advantages over the conventional solution phase TGS as the resulting products can be efficiently analysed and separated.

Figure 4: Monitoring of G4·Au@Fe3O4 mediated target guided synthesis.

HPLC chromatogram of the supernatant collected following the modified separation protocol; HPLC analysis using (a) G4·Au@Fe3O4 MNPs and (b) dsDNA·Au@Fe3O4. (c) ESI-MS analysis of the three fractions collected from the HPLC analysis using G4·Au@Fe3O4 reveals the formation of compounds Tz 1, Tz 2 and Tz 3. (d) The molecular structures of compounds Tz 1, Tz 2 and Tz 3.

Simultaneously, the reaction was performed in the presence of MNPs functionalized with duplex DNA (dsDNA·Au@Fe3O4) (Supplementary Fig. 8) as the control and only one triazole compound Tz 2 (combination of alkyne 1a and azide 3) was detected in MS-HPLC analysis (Fig. 4b). This protocol thus validates products Tz 1 (alkyne 1a and azide 11) and Tz 3 (alkyne 1a and azide 7) as the selective in situ lead compounds for the G-quadruplex DNA target (Fig. 4c,d). Compound Tz 2 non-specifically binds to both quadruplex and duplex DNA. It is worth noting that all the lead compounds are derived from alkyne 1a, which indicates that the DNA templates preferentially select alkyne 1a over alkyne 1b and 1c. However, the solubility of these fragments in aqueous buffer may play a role in their selection. Other possible products were not formed or detected in considerable amount indicating that the corresponding azides may not be optimally oriented by the c-MYC G-quadruplex template to react with the alkyne partners. Moreover, the preferential formation of Tz 1 suggests that the c-MYC G-quadruplex selected the azide 11 due to its aromatic carboxamide group and positively charged amine side chain that facilitates ππ stacking with additional electrostatic interactions with the quadruplex DNA.

We then analysed the product distribution of the reaction mixture with G4·Au@Fe3O4 template at two different time points. By stirring the reaction for 2 days, the major lead Tz 1 and Tz 2 (exclusively formed by duplex DNA) were obtained in a percentage ratio of 65:35 (Supplementary Fig. 7). After 4 days, the formation of Tz 1 was increased compared to Tz 2 (78:22), while the other lead Tz 3 was not detected in the mixture (Supplementary Fig. 7). The formation of Tz 2 was not significantly increased by the G-quadruplex template with time suggesting weaker binding affinity of Tz 2 for the c-MYC G-quadruplex DNA. However, the formation of Tz 1 was greatly accelerated by G4 DNA template with increasing time. These observations lead us to conclude that the c-MYC G4·Au@Fe3O4 nano-template promoted the preferential formation of Tz 1 as the potent lead compound and it could not bind other weak alkyne-azide partners on short time scales.

To determine the regioselectivity of the triazole product Tz 1 formed by c-MYC G4·Au@Fe3O4 NP templated synthesis, we have carried out the cycloaddition of alkyne 1a and azide 11 under both thermal and Cu(I) catalysed conditions (Supplementary Fig. 9). The Cu(I) catalysed cycloaddition gave the 1,4-substituted triazole product and the thermal Huisgen cycloaddition between the corresponding azide and alkyne generated both the 1,4- and 1,5-substituted regioisomers. Both the compounds have identical mass and the 1,5-substituted triazole product has a slightly lower retention time. By comparing the HPLC retention times, we have observed that the c-MYC G4·Au@Fe3O4 NPs templated the 1,3-dipolar cycloaddition of alkyne 1a and azide 11 leading to the formation of the identical product as in the Cu(I) catalysed reaction (Supplementary Fig. 10). These results illustrate that the c-MYC G4·Au@Fe3O4 NPs promote the cycloaddition between the proximally oriented alkyne 1a and azide 11 in a regioselective manner resulting in the formation of the 1,4-regioisomer of Tz 1 (relative yield 44%; Supplementary Fig. 11).

Recovery and reuse of the c-MYC DNA nano-template

Next, we investigated the ability of the magnetically recovered c-MYC G4·Au@Fe3O4 nanoparticles to template the Huisgen cycloaddition using the same azide-alkyne fragments 1–12. After 6 days, the recovered c-MYC MNPs provided the triazole products Tz 1–3 with nearly similar product distribution (63:6:31) as the freshly prepared c-MYC G4·MNPs (Supplementary Fig. 12). The product distribution was found to be similar in the subsequent reaction cycle. In the third cycle, Tz 1 and Tz 2 were obtained while the formation of Tz 3 (the other G4-binding ligand) was not observed in the HPLC chromatogram. In the fourth and fifth cycle, Tz 1 was exclusively formed, indicating high recycling ability of the nano-template (Fig. 5). It also suggests that the recovered nano-template maintains its templating activity and facilitates the formation of its strong binder from the pool of azide and alkyne fragments.

Figure 5: Recycling of G4·Au@Fe3O4 nano-template.

Schematic representation of recyclable c-MYC G-quadruplex magnetic nano-template catalysed in situ screening protocol.

Tz 1 selectively binds c-MYC G-quadruplex over duplex DNA

To validate the compound Tz 1 as the best binding ligand for c-MYC G-quadruplex DNA over duplex DNA, we have synthesized the three in situ lead products Tz 1–3 by the Cu(I) catalysed azide-alkyne cycloaddition from their respective alkyne/azide precursors38 (Supplementary Figs 13 and 14) and compared their stabilization potential using Förster resonance energy transfer (FRET) based melting assay39. We have used 5′-FAM and 3′-TAMRA-labelled c-MYC G-quadruplex (100 nM) and a control duplex DNA sequence (100 nM) to measure the stabilization potential and selectivity of the triazole products towards the DNA targets. Figure 6a–c demonstrates the melting profile of c-MYC and dsDNATm) in the presence of various concentration of each compound (Table 1). The compound Tz 1 showed a maximum stabilization potential for c-MYC at only 1 μM ligand concentration (ΔTm=19.3±0.96 °C) and a negligible stabilization potential towards duplex DNA (ΔTm=0.86±0.04 °C). The other lead compound Tz 3 exhibited a ΔTm value of 11.14±0.28 °C for c-MYC G4 DNA and 1.61±0.12 °C for duplex DNA at 1 μM concentration. Consistent with the duplex DNA templated synthesis, the compound Tz 2 showed stabilization potential for both c-MYC G4 DNA (ΔTm=8.17±0.41 °C) and duplex DNA (ΔTm=8.41±0.21 °C). These observations are in strong agreement with the trend obtained in the DNA·MNP guided synthesis. The FRET melting analysis thus revealed that the compound Tz 1 showed better stabilization potential (ΔTm) towards c-MYC G-quadruplex DNA over dsDNA compared to other triazole derivatives.

Figure 6: Biophysical analyses for the binding of lead compounds to c-MYC.

(ac) FRET melting profiles of 100 nM c-MYC G-quadruplex (Tm=70.9±1.2 °C) and dsDNA (Tm=61.3±2.1 °C) with increasing amounts of triazole products Tz 1, 2 and 3 (0–10 μM) in 60 mM potassium cacodylate buffer, pH=7.4. (di) Fluorescence responses of Tz 13 (1 μM) upon titration with c-MYC G-quadruplex DNA and duplex DNA.

Table 1 Stabilization potential (ΔTm) values by FRET melting experiments and dissociation constants measured by fluorescence titration.

FRET competition experiment was performed to evaluate the selectivity of Tz 1 for the c-MYC G-quadruplex DNA over duplex DNA (Supplementary Fig. 15). The ΔTm value of ligand Tz 1 for the c-MYC quadruplex showed a negligible change in the presence of 20 equivalent excess of dsDNA, indicating high selectivity of Tz 1 for the quadruplex over duplex DNA. In addition, the circular dichroism (CD) spectra for the c-MYC quadruplex show that Tz 1, even at high concentrations, did not perturb the parallel conformation of c-MYC G-quadruplex DNA (Supplementary Fig. 16).

As the carbazole derivatives are fluorescent, the binding affinities of the in situ lead compounds Tz 1, 2 and 3 for both quadruplex and duplex DNA were investigated by fluorescence titration (Fig. 6d–i). Fluorescence binding titration revealed that these carbazole derivatives are environmentally sensitive probes for the G-quadruplex36,40. The major lead compound Tz 1 exhibited a selective fluorescence enhancement (3.7-fold) upon binding with G-quadruplex with a 33 nm blueshift, whereas it barely showed any enhancement upon titration with duplex DNA. Compound Tz 2 showed enhanced fluorescence intensity (2.5-fold) with a significant blueshift of 40 nm in the presence of both c-MYC G-quadruplex and dsDNA. The significant blueshift observed for compounds Tz 1 and Tz 2 containing the electron donor and acceptor motifs, indicated their binding with the hydrophobic sites of the DNA. In comparison, Tz 3 produced a slight wavelength change (7 nm redshift) with a 1.9-fold increase in fluorescence intensity upon addition of c-MYC G-quadruplex. The fluorescence experiments further indicated that Tz 1 is selective for the c-MYC quadruplex DNA compared to Tz 2 and Tz 3 and it has high affinity for MYC quadruplex (KD=0.17±0.01 μM) (Table 1, Supplementary Fig. 17).

The FRET melting analysis and fluorescence titration results are consistent with the results obtained in c-MYC G4·Au@Fe3O4 NP templated target guided synthesis approach. The major lead compound Tz 1 containing two protonable tertiary amine side chains strongly interacts with quadruplex compared to the second lead compound Tz 3 that contains one amine side chain. In addition, the minor lead Tz 2 lacking the aromatic carboxamide group was formed as a major product in the presence of duplex DNA template, which further indicates that compounds with extended aromatic system can selectively target G-quadruplex over duplex DNA. The triazole compound Tz 1 that showed high affinity for the c-MYC G-quadruplex DNA, was selected for carrying out subsequent biological assays to highlight the importance of this methodology to discover important leads for G-quadruplex specific drug development.

Downregulation of c-MYC expression by Tz 1

We have also assessed the biological activity of Tz 1 in HCT116 colorectal adenocarcinoma cancer cell line. HCT116 has been reported as a model cell line for monitoring the c-MYC expression in living cells41,42. Fluorescence microscopic images of Tz 1 treated HCT116 cells reveals that Tz 1 permeates cell and nuclear membranes and preferentially localizes in the nuclei of the cells (Fig. 7a–c). We then evaluated the short-term growth inhibitory activity of Tz 1 in HCT116 cell line using MTT assay. Compound Tz 1 showed strong inhibitory acitivity on the proliferation of HCT116 cells in a dose-dependent manner, with an IC50 value of 2.1±0.1 μM at 24 h.

Figure 7: Biological validation of Tz 1 as c-MYC G4 stabilizer in cancer cells.

Fluorescence microscopic images of HCT116 cells incubated with Tz 1 and DAPI, Scale bar, 10 μm; cells stained with (a) DAPI and (b) Tz 1 and (c) co-localization of Tz 1 and DAPI. (d) Schematic representation of G-quadruplex-mediated control over c-MYC expression in HCT116 cancer cell line. (e) A reciprocal translocation in the CA46 Burkitt’s lymphoma cell line between the IgH heavy chain gene of chromosome 14 and the MYC gene on chromosome 8—NT mRNA expression is under the control of G-quadruplex forming region and T mRNA expression is independent of G-quadruplex. The NHE III1 region moved along with exon 1 produces no mRNA product; therefore represents expression form NT allele; whereas, exon 2 mRNAs are produced from both T and NT allele. (f) Immunoreactive bands of c-MYC and GAPDH protein expression as analysed by Western blot. (g) Concentration dependent downregulation of c-MYC mRNA and protein levels in HCT116 cells after treatment with compound Tz 1 for 24 h. (h) Exon-specific qRT-PCR assay with the CA46 Burkitt’s lymphoma cell line after 24 h treatment with Tz 1. (n=3, ±s.e.m.)

Next, we have evaluated the effect of Tz 1 on the transcriptional and the translational level of c-MYC gene. qRT-PCR analysis showed that Tz 1 reduced the transcription of c-MYC gene by 44 and 79% (normalized to GAPDH expression) at 1 and 2 μM concentrations, respectively, compared to the untreated cells. Western blot analysis corroborated the inhibitory activity of Tz 1 on the c-MYC expression by suppressing the c-MYC protein levels by 39 and 74% at 1 and 2 μM treatment, respectively. The expression of GAPDH in HCT116 cells remained unaltered by Tz 1 (Fig. 7f,g).

To further evaluate whether the observed c-MYC inhibition by Tz 1 was dependent on the ligand mediated G-quadruplex stabilization in the c-MYC promoter region, CA46 Burkitt’s lymphoma cell line was used to perform the exon-specific assay41,42. In CA46 cell line, the transcription of MYC exons are differentially regulated; exon 1, which generally remains untranslated, are transcribed under the control of G-quadruplex forming NHE III1 region. Whereas exon 2, which is predominantly responsible for MYC protein expression, is independent of G-quadruplex regulation due to the translocation occurred between the chromosome 8 (MYC gene) and 14 (IgH heavy chain gene). Thus the transcription of exon 2 mainly represents the MYC expression from the G-quadruplex-lost enhancer element of IgH heavy chain. This translocational alteration of the MYC gene locus renders the MYC protein expression unaffected to the inhibition by G-quadruplex stabilization. Using this model, we have demonstrated the G-quadruplex stabilizing ability of Tz 1 by independently monitoring the two MYC mRNA products produced within the CA46 cell line upon ligand treatment.

The qRT-PCR assay revealed that Tz 1 significantly induced exon-specific downregulation of MYC expression in a dose-dependent manner. It caused a noteworthy inhibition of exon 1 transcription (95% at 1 μM and 98% at 2 μM concentration), which is regulated by G-quadruplex formation, while transcription from exon 2 remains unaffected after 24 h treatment with Tz 1 (Fig. 7h). Thus, on the basis of the observed exon-specific effect of Tz 1, we can conclude that Tz 1 binds and stabilizes the G-quadruplex structure in c-MYC P1 promoter and specifically reduces c-MYC expression in cancer cells.

It is well documented that c-MYC plays a critical role in the regulation of the cellular fate between apoptosis and necrosis and therefore quadruplex interacting molecule that can repress c-MYC expression can drive cells towards apoptosis43. We investigated the ability of Tz 1 to induce cell apoptosis in HCT116 cells by flow cytometry. Tz 1 induced apoptotic cell death in a dose-dependent manner, as demonstrated by the dual staining with propidium iodide (PI) and Annexin V-FITC. The population of the apoptotic cells was increased significantly in the presence Tz 1, while there was no remarkable increase of necrotic cells upon 24 h treatment (Supplementary Fig. 18). The observed cellular effect of the lead compound Tz 1 is likely due to its interaction with the G-quadruplex DNA in the c-MYC promoter region.

It may be possible that Tz 1 can interact with other quadruplexes; among which we have only demonstrated its interaction with c-MYC promoter quadruplex DNA. However, this is not surprising as many drugs, even when approved; simultaneously target a set of signalling genes that ultimately lead to apoptosis44,45. In this regard, the compound of our interest may exert cellular apoptosis by simultaneous execution of c-MYC G-quadruplex stabilization and other secondary cellular effects.


In this work, we have established the use of magnetic nanoparticle-linked c-MYC G-quadruplex as a template for covalently assembling potent azide-alkyne partners to generate high-affinity quadruplex ligands. This methodology using DNA nano-templates for metal free Huisgen cycloaddition offers several advantages: First, it reduces the time required for the conventional laborious chemical synthesis of potent candidates and their biological binding/screening assay. Second, it provides a large surface with more number of local DNA catalytic sites for better interaction of the reacting fragments on the nano-surface. Thirdly, it enables efficient isolation of the in situ lead compound by simple magnetic decantation and lastly, it prevents the wastage of commercial DNA sequences by allowing the recovery and reuse of DNA magnetic nano-templates. This innovative approach has been used for a model library of azide and alkyne building blocks to obtain two 1,4-triazole lead compounds (out of 33 possible triazole products of 1,4-regiochemistry) for the G-quadruplex target. The major lead compound shows high binding affinity for c-MYC G-quadruplex DNA over duplex DNA, localizes exclusively into the nucleus, inhibits the c-MYC expression by targeting the c-MYC promoter G-quadruplex and induces apoptosis in HCT116 cells. We anticipate that this proof-of-concept study would pave the way for the design and fabrication of biomolecule immobilized magnetic nano-constructs, exhibiting potentially important impacts both in bionanotechnology and biomedical research.


Chemical synthesis

Detailed procedures for the synthesis of all new compounds and their characterization are provided in Supplementary Methods (For 1H and 13C NMR spectra of all compounds, Supplementary Methods and Supplementary Figs 19–36).

Synthesis of Fe3O4 nanoparticles

The Fe3O4 nanoparticles were prepared by co-precipitation technique. This method uses ferric and ferrous ions in a 1:2 molar ratio in basic solutions. An aqueous solution of FeCl3 (4 ml, 1 M) and FeCl2 (1 ml, 2 M in 2 M HCl) was mixed and added into diluted NH3 solution (50 ml, 0.7 M). The reaction mixture was stirred for 30 min at RT. Then, the precipitate was isolated by magnetic decantation, stirred with diluted HClO4 (50 ml, 2 M) and then collected by centrifugation. The residue was finally made up to 50 ml with deionized water.

Synthesis and characterization of Au@Fe3O4 nanoparticles

An aqueous solution of HAuCl4 (2.26 ml, 2.0 mg ml–1) was mixed with 15.75 ml deionized water and then heated to boiling. Then, 0.75 ml of Fe3O4 nanoparticle solution was added into the reaction mixture followed by the addition of sodium citrate (0.75 ml, 80 mM) with continuous stirring. The colour of the solution was gradually changed from brown to burgundy. The reaction mixture was heated to 85 °C under stirring for 5 min. After cooling, the solution was sonicated for 15 min, and then Au@Fe3O4 NPs were collected using a magnet, washed three times and redispersed in pure water.

The prepared Au@Fe3O4 NPs were characterized in 100 mM Tris-KCl buffer (pH 7.4) by ultraviolet-visible absorption spectroscopy (Cary Win 300 ultraviolet-visible spectrophotometer using quartz cuvette of path length 1 mm at 25 °C), CD spectroscopy (Jasco J-815), TEM (JEOL 1200 EX electron microscope) and atomic force electron microscopy (NT-MDT instrument in semicontact mode with a resonance frequency of 120 kHz).

Synthesis of DNA coated Au@Fe3O4 NPs

All buffers and solutions were bubbled with N2 and degassed to avoid oxidative dimerization of thiolated DNA sequences into disulfide dimers. Thiolated DNA attached nanoparticle probes were synthesized by mixing an aqueous dispersion of Au@Fe3O4 nanoparticles (100 μl) with 100 μl 5′-thiol-capped c-MYC G-quadruplex (oligonucleotide concentration is 100 μM in 100 mM Tris-KCl buffer, pH 7.4). After standing for 16 h, the nanoparticles were separated using magnet and washed with 100 mM Tris-KCl buffer (pH 7.4). The volume of the nanoparticle solution was made up to 100 μl with the buffer. Duplex DNA was also attached on the nanoparticle surface by following the same protocol.

The HPLC purified thiol-capped DNAs were supplied by Sigma-Aldrich. The sequences of the DNAs are as follows:



β-Mercaptoethanol mediated thiol exchange reaction

Au@Fe3O4 nanoparticle was surface functionalized with different concentrations of quadruplex DNA (10–50 μM). The DNA attached nanoparticles were then separated by a magnet and washed 3 to 4 times with Tris-KCl buffer, pH 7.4. β-Mercaptoethanol (β-ME) was added (final concentration 12 mM) to the oligonucleotide-modified nanoparticles in 100 mM Tris-KCl buffer (pH 7.4). After 18 h incubation at room temperature with intermittent shaking, the solutions containing the displaced oligonucleotides were separated from the Au@Fe3O4 nanoparticles using an external magnet. The supernatant was then subjected to Native PAGE to determine the surface functionalization of nanoparticles with thiolated oligonucleotides.

General procedure for G4·Au@Fe3O4 templated cycloaddition

To a suspension of G-quadruplex nano-template G4·Au@Fe3O4 (10 μl) in 20 μl Tris-KCl buffer (100 mM, pH 7.4), alkynes 1a–c followed by azides 212 were added. The stock solutions of all alkynes and azides were prepared in 5% DMSO solution and then serially diluted in 100 mM Tris-KCl buffer. Final reagent concentrations were as follows: alkyne (0.6 μM), azide (2.4 μM). The mixture containing the nano-template and azide-alkyne building blocks was stirred at room temperature. The cycloaddition products were identified by optimizing the separation protocols. After 2, 4 and 6 days of reaction, the G4·Au@Fe3O4 NPs were separated from the reaction mixture using a magnet and washed thrice with 100 mM Tris-KCl buffer, pH 7.4 (100 μl) to remove the unreacted starting materials. Subsequently, the nano-template was dispersed in 100 mM Tris-KCl buffer, pH 7.4 (50 μl) and the dispersion was then heated for 5 min at 65 °C. The nano-template was again separated instantly by magnetic decantation and the supernatant was analysed by HPLC analysis. The HPLC fractions corresponding to different peaks were identified by ESI-MS spectroscopy.

Control experiment using duplex DNA functionalized nanoparticles (ds ·Au@Fe3O4 NPs) was performed using similar experimental conditions. The HPLC analysis was carried out using 5.0 μm ODS2 reverse phase column (4.6 × 250 mm) using 254 nm detection wavelength. Flow rate was 0.5 ml min–1 CH3CN/H2O (90:10) in 0.1% TFA over 20 min.

FRET melting analysis

FRET melting experiments were carried out with a 100 nM oligonucleotide concentration in 60 mM potassium cacodylate buffer, pH 7.4. All HPLC purified dual labelled DNA oligonucleotides were purchased from Sigma-Aldrich. 5′-FAM and 3′-TAMRA-labelled DNA sequences were annealed at a concentration of 200 nM by heating at 95 °C for 5 min followed by gradual cooling to room temperature at a controlled rate of 0.1 °C min–1. Dual fluorescently labelled DNA oligonucleotides used in these experiments are:



FRET based screening assay was performed on a real-time PCR apparatus (Light Cycler 480 II System) by incubating the dual labelled DNA oligonucleotides (100 nM) with 1 μM of each triazole derivatives Tz 1–3 separately for 1 h. Fluorescence measurements were taken with an excitation wavelength of 483 nm and a detection wavelength of 533 nm at intervals of 1 °C over the range of 37–95 °C. Melting temperatures were calculated using Origin Pro 8 data analysis. Titrations experiments were performed by adding different concentration of Tz 1, Tz 2 and Tz 3 separately (0.3, 0.5, 0.8, 1.0, 2.0, 3.0, 5.0, 7.0 and 10.0 μM) to 100 nM solution of dual labelled c-MYC and duplex DNA in 60 mM potassium cacodylate buffer (pH 7.4). In FRET competition experiment, the concentration of Tz 1 was kept at 1.0 μM in all sets. The competitor duplex DNA was added to 100 nM c-MYC G-quadruplex sequence at final concentration of 100 nM, 500 nM, 1.0 μM and 2.0 μM.

Circular dichroism spectroscopy

CD spectra were recorded on a JASCO J-815 spectrophotometer using a 1 mm path-length quartz cuvette. Aliquots of ligand Tz 1 were added in increments to pre-annealed c-MYC G-quadruplex DNA (5′-GGGGAGGGTGGGGAGGGTGGGG-3′) in Tris-KCl (100 mM) buffer at pH 7.4. The DNA concentration used was 10 μM. The CD spectra represented an average of three scans and were smoothed and zero corrected. Final analysis of the data was carried out using Origin 8.0.

Fluorimetric titration

The fluorescence spectra were recorded on a Horiba Jobin Yvon Fluoromax 3 instrument at 25 °C in a 10 mm path-length quartz cuvette with filtered 100 mM Tris-KCl buffer (pH 7.4). Fluorescence titrations were performed with successive addition of the DNA solution into the 1 μM ligand solution. The binding constants were calculated using the following Hill 1 equation (1) with Origin Pro 8.0:

where F is the fluorescence intensity, Fmax is the maximum fluorescence intensity, F0 is the fluorescence intensity in the absence of DNA and KD is the dissociation constant.

In this experiment, following DNA sequences were utilised:



Cell culture and viability assay

HCT116 cell line (ATCC) was a kind gift from Dr Susanta Roychoudhury, Indian Institute of Chemical Biology (Kolkata). CA46 cell line was procured from ATCC. The cells were cultivated at 37 °C in 5% CO2 atmosphere and maintained in DMEM (Dulbecco’s modified Eagle Medium, Himedia Cell Culture)+10% FBS (GIBCO, Heat inactivated, US origin, catalogue number 10082147) and RPMI 1640 (GIBCO, catalogue number 11875093) medium +20% FBS, respectively, containing 1% anti-anti (GIBCO, catalogue number 15240062). HCT116 cells were passaged by dissociation with 1X trypsin-EDTA (GIBCO, catalogue number 15400054) and CA46 cultures were maintained by centrifugation with subsequent resuspension.

For viability assays, 6,000 cells were seeded per well in 96-well microtiter plates for 24 h. To monitor the ligand induced cell death, HCT116 cells were exposed with various concentrations of triazole Tz 1 for 24 h. Cell survival was assayed by the MTT method (catalogue number M6494). Absorbance (OD570) obtained from control untreated cells was taken as 100% and relative percentage decrease in absorbance was calculated in response to ligand treatment. Data were calculated as the percentage of cell viability. IC50 values were determined with Origin Pro 8 software using nonlinear curve fitting.

Fluorescence microscopy

The HCT116 cells were plated in six-well plates and treated with 5 μM Tz 1 for 8 h. After the incubation, the cells were washed with PBS and fixed for 12 min with 1:1 acetone/methanol at –20 °C. The cells were rinsed thrice in PBS, stained with DAPI and kept at room temperature in the dark for 10 min. The cells were then washed twice with PBS, examined and immediately photographed under a fluorescence microscope (Evos FL cell imaging system, ThermoFisher Scientific Ltd.).

qRT-PCR analysis

Colorectal cancer cell line HCT116 cells were treated with two different concentrations (1.0 and 2.0 μM) of triazole ligand Tz 1. Total RNA from treated and control cells were prepared using the trizol kit according to the manufacturer’s protocol (ThermoFisher Scientific, catalogue number 15596018) after 24 h. Reverse transcription was performed using the high capacity cDNA reverse transcription kit (Applied Biosystems, catalogue number 4368814) by following the kit manual. The prepared cDNA was amplified by PCR using Power SYBR Green PCR Master Mix (ThermoFisher Scientific, catalogue number 4367659) with the forward and reverse primers in Light Cycler 480 II (Roche).

Primers used in the amplification of c-MYC and GAPDH gene:





The PCR mixture (20 μl) contained 500 nM of each primer, 5 μl of cDNA template and 10 μl of SYBR green mix and the rest of the volume is made up with nuclease free water. The thermal cycling conditions were 10 min at 95 °C and then 40 cycles of 15 s at 95 °C and 60 s at 60 °C. The relative mRNA expression was determined by the arithmetic calibrator (2−ΔΔCT) and the difference in c-MYC expression was expressed as fold changes.

Western blot analysis

After 24 h incubation of HCT116 cells with the above mentioned concentrations of Tz 1, cells were washed once with PBS (pH 7.4) and lysed with ice-cold cell lysis buffer (20 mM Tris, 100 mM NaCl, 1 mM EDTA in 0.5% Triton X-100). Cell lysate was collected from the treated and untreated cells, and the total protein content was estimated by Folin–Lowry method. Sixty micrograms of protein from each cell treatment was loaded and separated by 12% SDS–PAGE and transferred to nitrocellulose membrane. The membranes were blocked, washed and probed using 1:700 dilution of anti-c-MYC (Invitrogen, catalogue number 710007) and anti-GAPDH antibodies (Invitrogen, catalogue number 398600) for overnight at room temperature. The blots were washed and immunoreactive bands were incubated with a 1:2,000 dilution of respective enzyme conjugated secondary antibodies for 2 h at room temperature. Binding signals were visualized with enzyme substrate (MP) and relative band intensities were determined using ImageJ software.

Exon-specific assay

CA46 cells were treated with Tz 1 at 1 and 2 μM concentration for 24 h. The cells were then washed in PBS twice and the RNA was isolated using the trizol kit according to the manufacturer’s protocol (ThermoFisher Scientific, catalogue number 15596018). Reverse transcription of the RNA was performed using the high capacity cDNA reverse transcription kit (Applied Biosystems, catalogue number 4368814). The cDNA was amplified in PCR using Power SYBR Green PCR Master Mix (ThermoFisher Scientific, catalogue number 4367659) with the exon 1 and exon 2 forward and reverse primers in Light Cycler 480 II (Roche) system. For exon 1 and exon 2, the relative mRNA expression was normalized by the GAPDH expression.






FACS analysis for apoptosis

HCT116 cells were treated with increasing concentrations of Tz 1 for 24 h and collected by trypsinization. Cell pellet was resuspended in 500 μl 1X Annexin V binding buffer (0.01 M HEPES, pH 7.4, 0.14 M NaCl, 2.5 mM CaCl2) and incubated with 5 μl FITC-Annexin V (ThermoFisher Scientific, catalogue number A13199) and 1 μl 100 μg ml–1 propidium iodide (ThermoFisher Scientific, catalogue number P3566) for 15 min. Finally flow cytometry was performed by BD-LSR flow cytometer (BD Biosciences, SanDiego, CA, USA) for apoptosis assay. Approximately 10,000 HCT116 cells were monitored for each sample.

Data availability

The authors declare that all data supporting the findings of this study are available in the article and in Supplementary Information file. Additional informations are available from the corresponding author upon request.

Additional information

How to cite this article: Panda, D. et al. Target guided synthesis using DNA nano-templates for selectively assembling a G-quadruplex binding c-MYC inhibitor. Nat. Commun. 8, 16103 doi: 10.1038/ncomms16103 (2017).

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1

    Mamidyala, S. K. & Finn, M. G. In situ click chemistry: probing the binding landscapes of biological molecules. Chem. Soc. Rev. 39, 1252–1261 (2010).

    CAS  PubMed  Google Scholar 

  2. 2

    Lewis, W. G. et al. Click chemistry in situ: acetylcholinesterase as a reaction vessel for the selective assembly of a femtomolar inhibitor from an array of building blocks. Angew. Chem. Int. Ed. Engl. 41, 1053–1057 (2002).

    CAS  PubMed  Google Scholar 

  3. 3

    Manetsch, R. et al. In situ click chemistry: enzyme inhibitors made to their own specifications. J. Am. Chem. Soc. 126, 12809–12818 (2004).

    CAS  PubMed  Google Scholar 

  4. 4

    Tieu, W. et al. Optimising in situ click chemistry: the screening and identification of biotin protein ligase inhibitors. Chem. Sci. 4, 3533–3537 (2013).

    CAS  Google Scholar 

  5. 5

    Suzuki, T. et al. An unexpected example of protein-templated click chemistry. Angew. Chem. Int. Ed. Engl. 49, 6817–6820 (2010).

    CAS  PubMed  Google Scholar 

  6. 6

    Agnew, H. D. et al. Iterative in situ click chemistry creates antibody-like protein-capture agents. Angew. Chem. Int. Ed. 48, 4944–4948 (2009).

    CAS  Google Scholar 

  7. 7

    Mocharla, V. P. et al. In situ click chemistry: enzyme-generated inhibitors of carbonic anhydrase II. Angew. Chem. Int. Ed. 44, 116–120 (2005).

    CAS  Google Scholar 

  8. 8

    Di Antonio, M. et al. Selective RNA versus DNA G-quadruplex targeting by in situ click chemistry. Angew. Chem. Int. Ed. 51, 11073–11078 (2012).

    CAS  Google Scholar 

  9. 9

    Hu, M. H. et al. A new application of click chemistry in situ: development of fluorescent probe for specific G-quadruplex topology. Sci. Rep. 5, 17202 (2015).

    ADS  CAS  PubMed  PubMed Central  Google Scholar 

  10. 10

    Gonzalez, V. & Hurley, L. H. The c-MYC NHE III1: function and regulation. Annu. Rev. Pharmacol. 50, 111–129 (2010).

    CAS  Google Scholar 

  11. 11

    Siddiqui-Jain, A., Grand, C. L., Bearss, D. J. & Hurley, L. H. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc. Natl Acad. Sci. USA 99, 11593–11598 (2002).

    ADS  CAS  PubMed  Google Scholar 

  12. 12

    Neidle, S. Quadruplex nucleic acids as novel therapeutic targets. J. Med. Chem. 59, 5987–6011 (2016).

    CAS  PubMed  Google Scholar 

  13. 13

    Chambers, V. S. et al. High-throughput sequencing of DNA G-quadruplex structures in the human genome. Nat. Biotechnol. 33, 877–881 (2015).

    PubMed  PubMed Central  Google Scholar 

  14. 14

    Collie, G. W. & Parkinson, G. N. The application of DNA and RNA G-quadruplexes to therapeutic medicines. Chem. Soc. Rev. 40, 5867–5892 (2011).

    CAS  PubMed  Google Scholar 

  15. 15

    Balasubramanian, S. & Neidle, S. G-quadruplex nucleic acids as therapeutic targets. Curr. Opin. Chem. Biol. 13, 345–353 (2009).

    CAS  PubMed  PubMed Central  Google Scholar 

  16. 16

    Monchaud, D. & Teulade-Fichou, M. P. A hitchhiker’s guide to G-quadruplex ligands. Org. Biomol. Chem. 6, 627–636 (2008).

    CAS  PubMed  Google Scholar 

  17. 17

    Seenisamy, J. et al. The dynamic character of the G-quadruplex element in the c-MYC promoter and modification by TMPyP4. J. Am. Chem. Soc. 126, 8702–8709 (2004).

    CAS  PubMed  Google Scholar 

  18. 18

    Seenisamy, J. et al. Design and synthesis of an expanded porphyrin that has selectivity for the c-MYC G-quadruplex structure. J. Am. Chem. Soc. 127, 2944–2959 (2005).

    CAS  PubMed  Google Scholar 

  19. 19

    Ou, T. M. et al. Inhibition of cell proliferation by quindoline derivative (SYUIQ-05) through its referential Interaction with c-myc promoter G-quadruplex. J. Med. Chem. 54, 5671–5679 (2011).

    CAS  PubMed  Google Scholar 

  20. 20

    Felsenstein, K. M. et al. Small molecule microarrays enable the identification of a selective, quadruplex-binding inhibitor of MYC expression. ACS Chem. Biol. 11, 139–148 (2016).

    CAS  Google Scholar 

  21. 21

    Gupta, A. K. & Gupta, M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials 26, 3995–4021 (2005).

    CAS  PubMed  Google Scholar 

  22. 22

    Berry, C. C. Possible exploitation of magnetic nanoparticle-cell interaction for biomedical applications. J. Mater. Chem. 15, 543–547 (2005).

    CAS  Google Scholar 

  23. 23

    Zeng, H. & Sun, S. H. Syntheses, properties and potential applications of multicomponent magnetic nanoparticles. Adv. Funct. Mater. 18, 391–400 (2008).

    CAS  Google Scholar 

  24. 24

    Gao, J. H., Gu, H. W. & Xu, B. Multifunctional magnetic nanoparticles: design, synthesis, and biomedical applications. Acc. Chem. Res. 42, 1097–1107 (2009).

    CAS  PubMed  Google Scholar 

  25. 25

    Colombo, M. et al. Biological applications of magnetic nanoparticles. Chem. Soc. Rev. 41, 4306–4334 (2012).

    CAS  PubMed  Google Scholar 

  26. 26

    Zhang, Y., Lu, F., Yager, K. G., van der Lelie, D. & Gang, O. A general strategy for the DNA-mediated self-assembly of functional nanoparticles into heterogeneous systems. Nat. Nanotechnol. 8, 865–872 (2013).

    ADS  CAS  PubMed  Google Scholar 

  27. 27

    Lo, C. K., Xiao, D. & Choi, M. M. F. Homocysteine-protected gold-coated magnetic nanoparticles: synthesis and characterisation. J. Mater. Chem. 17, 2418–2427 (2007).

    CAS  Google Scholar 

  28. 28

    Robinson, I., Tung, L. D., Maenosono, S., Walti, C. & Thanh, N. T. K. Synthesis of core-shell gold coated magnetic nanoparticles and their interaction with thiolated DNA. Nanoscale 2, 2624–2630 (2010).

    ADS  CAS  PubMed  Google Scholar 

  29. 29

    Ban, Z. H., Barnakov, Y. A., Golub, V. O. & O’Connor, C. J. The synthesis of core shell iron@gold nanoparticles and their characterization. J. Mater. Chem. 15, 4660–4662 (2005).

    CAS  Google Scholar 

  30. 30

    Creighton, J. A. & Eadon, D. G. Ultraviolet visible absorption-spectra of the colloidal metallic elements. J. Chem. Soc. Faraday Trans. 87, 3881–3891 (1991).

    CAS  Google Scholar 

  31. 31

    Xu, Z., Hou, Y. & Sun, S. Magnetic core/shell Fe3O4/Au and Fe3O4/Au/Ag nanoparticles with tunable plasmonic properties. J. Am. Chem. Soc. 129, 8698–8699 (2007).

    CAS  PubMed  Google Scholar 

  32. 32

    Demers, L. M. et al. A fluorescence-based method for determining the surface coverage and hybridization efficiency of thiol-capped oligonucleotides bound to gold thin films and nanoparticles. Anal. Chem. 72, 5535–5541 (2000).

    CAS  PubMed  Google Scholar 

  33. 33

    Ramsewak, R. S., Nair, M. G., Strasburg, G. M., DeWitt, D. L. & Nitiss, J. L. Biologically active carbazole alkaloids from Murraya koenigii. J. Agric. Food Chem. 47, 444–447 (1999).

    CAS  PubMed  Google Scholar 

  34. 34

    Schmidt, A. W., Reddy, K. R. & Knolker, H. J. Occurrence, biogenesis, and synthesis of biologically active carbazole alkaloids. Chem. Rev. 112, 3193–3328 (2012).

    CAS  PubMed  Google Scholar 

  35. 35

    Dhara, K., Mandal, T., Das, J. & Dash, J. Synthesis of carbazole alkaloids by ring-closing metathesis and ring rearrangement-aromatization. Angew. Chem. Int. Ed. 54, 15831–15835 (2015).

    CAS  Google Scholar 

  36. 36

    Panda, D. et al. A nucleus-imaging probe that selectively stabilizes a minor conformation of c-MYC G-quadruplex and down-regulates c-MYC transcription in human cancer cells. Sci. Rep. 5, 13183 (2015).

    ADS  CAS  PubMed  PubMed Central  Google Scholar 

  37. 37

    Risitano, A. & Fox, K. R. Influence of loop size on the stability of intramolecular DNA quadruplexes. Nucl. Acids Res. 32, 2598–2606 (2004).

    CAS  PubMed  Google Scholar 

  38. 38

    Rostovtsev, V. V., Green, L. G., Fokin, V. V. & Sharpless, K. B. A stepwise Huisgen cycloaddition process: copper(I)-catalyzed regioselective ‘ligation’ of azides and terminal alkynes. Angew. Chem. Int. Ed. 41, 2596–2599 (2002).

    CAS  Google Scholar 

  39. 39

    Mergny, J. L. et al. Telomerase inhibitors based on quadruplex ligands selected by a fluorescence assay. Proc. Natl Acad. Sci. USA 98, 3062–3067 (2001).

    ADS  CAS  PubMed  Google Scholar 

  40. 40

    Das, R. N., Debnath, M., Gaurav, A. & Dash, J. Environment-sensitive probes containing a 2,6-diethynylpyridine motif for fluorescence turn-on detection and induction of nanoarchitectures of human telomeric quadruplex. Chem.-Eur. J. 20, 16688–16693 (2014).

    CAS  PubMed  Google Scholar 

  41. 41

    Boddupally, P. V. et al. Anticancer activity and cellular repression of c-MYC by the G-quadruplex-stabilizing 11-piperazinylquindoline is not dependent on direct targeting of the G-quadruplex in the c-MYC promoter. J. Med. Chem. 55, 6076–6086 (2012).

    CAS  PubMed  PubMed Central  Google Scholar 

  42. 42

    Brown, R. V., Danford, F. L., Gokhale, V., Hurley, L. H. & Brooks, T. A. Demonstration that drug-targeted down-regulation of MYC in non-hodgkins lymphoma is directly mediated through the promoter G-quadruplex. J. Biol. Chem. 286, 41018–41027 (2011).

    CAS  PubMed  PubMed Central  Google Scholar 

  43. 43

    Hoffman, B. & Liebermann, D. A. Apoptotic signaling by c-MYC. Oncogene 27, 6462–6472 (2008).

    CAS  PubMed  Google Scholar 

  44. 44

    Thorn, C. F. et al. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet. Genom. 21, 440–446 (2011).

    CAS  Google Scholar 

  45. 45

    Vuddanda, P. R., Chakraborty, S. & Singh, S. Berberine: a potential phytochemical with multispectrum therapeutic activities. Expert Opin. Inv. Drug 19, 1297–1307 (2010).

    CAS  Google Scholar 

Download references


We dedicate this work to Professor Shankar Balasubramanian on the occasion of his 50th birthday. This research work is supported by the Department of Science and Technology [DST/SJF/CSA-01/2015–16]; and DST Nano Mission [SR/NM/NS-1034/2011(G)], India. J.D. thanks DST for a SwarnaJayanti fellowship; D.P. thanks CSIR India for a research fellowship; T.D. thanks DBT for research fellowship. We gratefully thank Mr Tanmoy Dalui for FACS analysis, IICB Kolkata and Vivek Chander and Dr Arun Bandyopadhyay, IICB for Fluorescence Imaging.

Author information




J.D. and D.P. designed the experiments. D.P. synthesized the compounds and performed HPLC. D.P. and P.S. performed TGS reactions and isolation of the leads. D.P. and P.S. carried out FRET, Fluorescence and CD spectroscopy. P.S. and T.D. performed biological experiments. J.D. supervised the experiments. All authors analysed the data and J.D. and P.S. wrote the manuscript.

Corresponding author

Correspondence to Jyotirmayee Dash.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Panda, D., Saha, P., Das, T. et al. Target guided synthesis using DNA nano-templates for selectively assembling a G-quadruplex binding c-MYC inhibitor. Nat Commun 8, 16103 (2017).

Download citation

Further reading


By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.


Quick links